Research PaperPersistence of specific antibodies after hepatitis B vaccination
References (20)
- et al.
Vaccines against hepatitis
Ann Inst Pasteur/Virol
(1986) - et al.
Hepatitis B vaccination: how long does protection last?
Lancet
(1984) - et al.
Hepatitis B vaccination: how long does protection last?
Lancet
(1984) - et al.
Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal)
Lancet
(1986) - et al.
When should at-risk infants be boosted with hepatitis B vaccine?
Lancet
(1987) - et al.
Hepatitis B vaccine — an overview
- et al.
Persistenz von Antikörpern gegen Hepatitis-B-Oberflächenantigen nach Impfung gegen Hepatitis B
Dtsch Med Wochenschr
(1985) - et al.
Hepatitis-B-Impfung — Wann ist eine Booster-Injektion nötig?
Schweiz Med Wochenschr
(1985) - et al.
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men
N Engl J Med
(1986) Hepatitis B vaccine
N Engl J Med
(1987)
Cited by (106)
Seroepidemiology of hepatitis B virus infection among adults in Singapore: A 12-year review
2013, VaccineCitation Excerpt :In our study, we considered anti-HBs titre ≥10 mIU/mL as the level of immunity to HBV. While it has been well known that anti-HBs titres decline rapidly within the first year following vaccination and slowly thereafter, having anti-HBs levels below 10 mIU/mL does not necessarily indicate loss of protection [35,36]. Vaccinated persons are still protected against HBV infection because a high proportion of vaccine recipients retain immunological memory and could mount an effective anamnestic response upon exposure to the virus [37,38].
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
2012, VaccineCitation Excerpt :Hypo-responders tend to have a shorter duration of detectable anti-HBsAg and therefore may not have long-term immunity to HBV infection [5]. It has also been shown that achieving and maintaining anti-HBsAg ≥ 100 mIU/mL is associated with long-term persistence of seroprotection [6,7]. Persons older than 40 years have a 25–50% non-responder rate [8], and patients receiving hemodialysis or those with diabetes have been reported to have a 30–40% non-responder rate [9].
Persistence of long-term immunity to hepatitis B among adolescents immunized at birth
2012, VaccineCitation Excerpt :We showed that children with post-primary vaccination anti-HBs levels of 10–99 mIU/mL were less likely to mount an anamnestic response when boosted than those with initial anti-HBs ≥100 mIU/mL, suggesting that strength of initial antibody response to vaccination may correlate with the development of immune memory. This association has been described in previous studies [12,17,26,27]. Memory B cells, which are capable of recognizing and responding to an antigen challenge and subsequently proliferating and differentiating into specific antibody producing plasma cells, must be efficiently engaged at primary vaccination.
The worldwide impact of vaccination on the control and protection of viral hepatitis B
2011, Digestive and Liver Disease